- Home
- LPTH vs LPTX Comparison
LPTH vs LPTX Comparison
Compare LPTH & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- LPTX
- Stock Information
- Founded
- LPTH 1985
- LPTX 2011
- Country
- LPTH United States
- LPTX United States
- Employees
- LPTH N/A
- LPTX N/A
- Industry
- LPTH Semiconductors
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPTH Technology
- LPTX Health Care
- Exchange
- LPTH Nasdaq
- LPTX Nasdaq
- Market Cap
- LPTH 128.3M
- LPTX 119.6M
- IPO Year
- LPTH 1996
- LPTX N/A
- Fundamental
- Price
- LPTH $2.93
- LPTX $0.38
- Analyst Decision
- LPTH Strong Buy
- LPTX Buy
- Analyst Count
- LPTH 3
- LPTX 2
- Target Price
- LPTH $4.67
- LPTX $8.00
- AVG Volume (30 Days)
- LPTH 183.9K
- LPTX 328.6K
- Earning Date
- LPTH 05-15-2025
- LPTX 08-11-2025
- Dividend Yield
- LPTH N/A
- LPTX N/A
- EPS Growth
- LPTH N/A
- LPTX N/A
- EPS
- LPTH N/A
- LPTX N/A
- Revenue
- LPTH $33,626,969.00
- LPTX N/A
- Revenue This Year
- LPTH $19.58
- LPTX N/A
- Revenue Next Year
- LPTH $44.50
- LPTX N/A
- P/E Ratio
- LPTH N/A
- LPTX N/A
- Revenue Growth
- LPTH 2.59
- LPTX N/A
- 52 Week Low
- LPTH $1.04
- LPTX $0.22
- 52 Week High
- LPTH $4.42
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- LPTH 55.46
- LPTX 50.42
- Support Level
- LPTH $2.90
- LPTX $0.38
- Resistance Level
- LPTH $3.25
- LPTX $0.44
- Average True Range (ATR)
- LPTH 0.18
- LPTX 0.04
- MACD
- LPTH -0.02
- LPTX -0.00
- Stochastic Oscillator
- LPTH 25.72
- LPTX 38.74
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .